
CLAIMS

1. An inhalable dry powder formulation comprising micronized particles of a compound of general formula (**I**) as (-) enantiomer,



(**I**)

wherein:

n is 0 or 1;

R_1 and R_2 may be the same or different, and are selected from the group consisting of:

- linear or branched ~~(~~C_1-C_6~~)~~ alkyl, optionally substituted ~~by~~with one or more halogen atoms;
- OR_3 wherein R_3 is a linear or branched ~~(~~C_1-C_6~~)~~ alkyl optionally substituted with one or more halogen atoms or C_3-C_7 cycloalkyl groups; and
- $HNSO_2R_4$ wherein R_4 is a linear or branched ~~(~~C_1-C_4~~)~~ alkyl optionally substituted with one or more halogen atoms,

wherein at least one of R_1 and R_2 is $HNSO_2R_4$;

and coarse carrier particles ~~of a carrier~~ made of a physiologically acceptable pharmacologically-inert material having a mass diameter of 150 to 400 micron

with a fissure index of at least 1.25;

wherein said compound is administered at a therapeutically effective single dose comprised between 300 μg and 1000 μg.

~~2. The inhalable powder according to claim 1, wherein the compound of general formula (I) is administered at a single dose comprised between 10 μg and 2000 μg.~~

~~3. The inhalable powder according to claim 2, wherein the single dose is comprised between 20 μg and 1000 μg.~~

~~4. The inhalable powder according to claim 3, wherein the single dose is comprised between 50 μg and 800 μg.~~

25. The inhalable powder according to claim 14, wherein the single dose is comprised between 300~~100~~ μg and 600 μg.

36. The inhalable powder according to claim 25, wherein the single dose is ~~100 μg or 200 μg,~~ 400 μg or 600 μg.

4. The inhalable powder according to any one of claims 1 to 3, wherein the compound of formula (I) is (-)-3-Cyclopropylmethoxy-4-methanesulfonylamino-benzoic acid 1-(3-cyclopropylmethoxy-4-difluoromethoxy-phenyl)-2-(3,5-dichloro-1-oxy-pyridin-4-yl)-ethyl ester (C2).

57. The inhalable powder according to any one of claims 1 to 46, wherein the physiologically acceptable pharmacologically-inert material is~~carrier comprises~~ a crystalline sugar selected from the group consisting of glucose, arabinose, maltose, saccharose, dextrose and lactose or a polyalcohol selected from the group consisting of mannitol, maltitol, lactitol and sorbitol.

68. The inhalable powder according to claim 57, wherein the sugar is lactose.

79. The inhalable powder according to claim 68, wherein the sugar is α-lactose monohydrate.

~~10. The inhalable powder according to any one of claims 1 to 9, wherein the carrier is in form of finely divided particles having a mass median diameter (MMD) equal to or of less than 10 micron.~~

811. The inhalable powder according to any one of the claims 1 to 79, wherein the ~~carrier is in form of~~ coarse carrier particles have~~ing~~ a mass diameter ~~of at least 50 micron.~~

~~12. The inhalable powder according to claim 11, wherein the mass diameter is greater than 80 micron.~~

~~13. The inhalable powder according to claim 12, wherein the mass diameter is~~ comprised between 210~~150~~ and 355~~400~~ micron.

~~14. The inhalable powder according to any one of claims 1 to 9, wherein the carrier comprises a mixture of coarse particles having a mass diameter comprised between 150 and 400 micron and finely divided particles with a MMD equal to or less than 10 micron.~~

915. The inhalable powder according to any one of the preceding claims ~~10 to 14~~, further comprising one or more additive materials selected form the group consisting of amino acids, water soluble surface active agents, lubricants and glidants.

1016. The inhalable powder according to claim 915, wherein the additive material is a lubricant.

11~~17~~. The inhalable powder according to claim 10~~16~~, wherein the additive material is magnesium stearate.

12~~18~~. The inhalable powder according to claim 11~~17~~, wherein magnesium stearate is present in an amount comprised 0.01 and 2% by weight based on the total weight of the formulation.

13~~19~~. The inhalable powder according to claim 12~~18~~, wherein the amount of magnesium stearate is comprised between 0.02 and 1% w/w.

14. The inhalable powder according to any one of the preceding claims, further comprising finely divided particles of a physiologically acceptable pharmacologically-inert material with a mass median diameter (MMD) equal to or less than 15 micron.

15~~20~~. A dry powder inhaler comprising an inhalable dry powder formulation according to any one of claims 1 to 14~~19~~.

16~~21~~. The inhalable dry powder formulation according to any one of claims 1 to 14~~19~~, for use for the prevention and/or treatment of a respiratory disease.

17. The inhalable dry powder formulation according to claims 16, wherein the disease is~~such as~~ asthma and chronic obstructive pulmonary disease (COPD).

18~~22~~. A package comprising an inhalable dry powder formulation according to any one of claims 1 to 14~~19~~ and a dry powder inhaler.

19. Use of the inhalable dry powder formulation according to any one of claims 1 to 14 in the manufacture of a medicament for the prevention and/or treatment of a respiratory disease.

20. The use according to claim 19, wherein the disease is asthma and chronic obstructive pulmonary disease (COPD).